• tascanz@muskaancaretrust.org.nz; office@muskaancaretrust.org.nz
  • +64 21231 8485
News Photo

Gene therapy is the future of medicine, but payment models have to catch up June 4, 2024 / BIO Events, Health, Latest News / By Clary Estes

Gene therapy is poised to break the stratosphere, providing many rare disease patients with an option out of their diseases. Whether innovations in CAR T-cell therapy or the rise of CRISPR, never before have patients had such a variety of therapeutic options becoming available.

And the future is here. Just last December, the U.S. Food and Drug Administration (FDA) approved the first two cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older—one of which utilizes CRISPR technology. 

However, one glaring issue is blocking the path to success: who pays for the treatment?
More information read here - https://bio.news/health/bio-2024-international-convention-gene-therapy-payment-models-bluebird-bio-vertex-pharmaceuticals/?fbclid=IwZXh0bgNhZW0CMTEAAR0Vn2LNtTHn4qcGwA7ffasyJQZyGJqzVut98f9J3OtWHTb9eCLK5PLr-Ik_aem_71qOwLShNmEfie4uslcTPA

Share This News


Do you want to get our quality service for your business?